Newsroom
- Press Release
19 September 25
CuraTeQ Biologics announces positive Phase 3 study results for Denosumab biosimilar
Read more - Press Release
04 July 25
CuraTeQ Biologics receives EC marketing authorization for Dazublys – Trastuzumab biosimilar
Read more - Press Release
26 April 25
CuraTeQ Biologics receives CHMP positive opinion for Dazublys – Trastuzumab biosimilar
Read more